Program
enlonstobart
Also written as “SG001”, “Enlonstobart” and “SYS6041, enlonstobart, bevacizumab”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Esophageal Squamous Cell Carcinoma · Stomach Neoplasms · Uterine Cervical Neoplasms · Ovarian Neoplasms, led by 2 companies.
Drug pageEnlonstobart: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Groupits history only | 1410 open or running | phase 3since Jan 16, 2023 | Feb 20, 2019 | Apr 2027phase 2 · NCT06136988 |
| Shanghai Runshi Pharmaceutical Technologyits history only | 11 open or running | phase 2since Nov 9, 2023 | Nov 9, 2023 | Jan 30, 2027phase 2 · NCT06132217 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 1 study since Feb 20, 2019.
- Apr 26, 2021Phase 2 study in Uterine Cervical NeoplasmsCSPC Pharmaceutical Group · NCT04886700 · 104 enrolled · China
- Jul 16, 2021Phase 2 study in Carcinoma, Ovarian EpithelialCSPC Pharmaceutical Group · NCT04983550 · 126 enrolled
- Sep 9, 2021Phase 2 study in Triple Negative Breast NeoplasmsCSPC Pharmaceutical Group · NCT05068141 · 79 enrolled · China
- Jan 16, 2023Phase 3 study in RecurrenceCSPC Pharmaceutical Group · NCT05715840 · 368 planned
- Jan 19, 2023Named enlonstobartINNProposed as its International Nonproprietary Name in WHO's List 128 · before, SG001
- Oct 13, 2023Phase 2 study in Colorectal NeoplasmsCSPC Pharmaceutical Group · NCT06089330 · 102 planned
- Nov 8, 2023Phase 2 study in Locally Advanced Unresectable Esophageal Squamous CarcinomaCSPC Pharmaceutical Group · NCT06136988 · 129 planned · China
- Nov 9, 2023Shanghai Runshi Pharmaceutical Technology’s first study: phase 2 study in Advanced Solid TumorNew to Shanghai Runshi Pharmaceutical TechnologyShanghai Runshi Pharmaceutical Technology · NCT06132217 · 168 planned · China
- May 12, 2025Phase 2 study in HER2-positive Gastric CancerCSPC Pharmaceutical Group · NCT06998771 · 153 planned
- Nov 13, 2025Phase 3 study in Esophageal Squamous Cell CarcinomaCSPC Pharmaceutical Group · NCT07251062 · 737 planned
- Dec 25, 2025Phase 3 study in HER2-positive Gastric CancerCSPC Pharmaceutical Group · NCT07332533 · 490 planned
- May 31, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT07633873 · 500 planned
- Jun 21, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT07672223 · 586 planned · China
- Jul 8, 2026Phase 2 study in Ovarian NeoplasmsCSPC Pharmaceutical Group · NCT07714668 · 171 planned · China
- Oct 26, 2026Phase 3 study in Esophageal Squamous Cell CarcinomaCSPC Pharmaceutical Group · NCT07924111 · 585 planned
Ahead
- Jan 30, 2027Primary completion: phase 2 study in Advanced Solid TumorShanghai Runshi Pharmaceutical Technology · NCT06132217
- Apr 2027Primary completion: phase 2 study in Locally Advanced Unresectable Esophageal Squamous CarcinomaCSPC Pharmaceutical Group · NCT06136988
- Sep 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT07633873
- Apr 30, 2028Primary completion: phase 2 study in Ovarian NeoplasmsCSPC Pharmaceutical Group · NCT07714668
TargetBeta
“A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
| sasanlimab | Pfizer | phase 3 | 4 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07924111Esophageal Squamous Cell Carcinoma | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Dec 30, 2029 | 585 |
| NCT07714668Ovarian Neoplasms · China | 2 | Recruiting | CSPC Pharmaceutical Group | Apr 30, 2028 | 171 |
| NCT07672223Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | CSPC Pharmaceutical Group | Sep 30, 2029 | 586 |
| NCT07633873Carcinoma, Non-Small-Cell Lung | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Sep 30, 2027 | 500 |
| NCT07332533HER2-positive Gastric Cancer | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Jun 30, 2032 | 490 |
| NCT07251062Esophageal Squamous Cell Carcinoma | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Dec 30, 2029 | 737 |
| NCT06998771HER2-positive Gastric Cancer | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Jun 30, 2028 | 153 |
| NCT06132217Advanced Solid Tumor · China | 2 | Not yet recruiting | Shanghai Runshi Pharmaceutical Technology | Jan 30, 2027 | 168 |
| NCT06136988Locally Advanced Unresectable Esophageal Squamous Carcinoma · China | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Apr 2027 | 129 |
| NCT06089330Colorectal Neoplasms | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Jul 2024 | 102 |
| NCT05715840Recurrence | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Jul 31, 2024 | 368 |
| NCT05068141Triple Negative Breast Neoplasms · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | Oct 1, 2022 | 79 |
| NCT04983550Carcinoma, Ovarian Epithelial | 2 | UNKNOWN | CSPC Pharmaceutical Group | Jan 2023 | 126 |
| NCT04886700Uterine Cervical Neoplasms · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | Dec 31, 2022 | 104 |
| NCT03852823Uterine Cervical Neoplasms · China | 1 | UNKNOWN | CSPC Pharmaceutical Group | Sep 2022 | 192 |
How it is read
Names in the registry
- “SG001”, 8 entries
- “Enlonstobart”, 3 entries
- “SYS6041, enlonstobart, bevacizumab”, 1 entry
- “Enlonstobart injection”, 1 entry
- “SYS6010+SG001+ physician's choice (Capecitabine or 5-FU)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Esophageal Squamous Cell Carcinoma, 2 studies
- Stomach Neoplasms, 2 studies
- Uterine Cervical Neoplasms, 2 studies
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.